Amarin and Esperion get a chance to reinforce their lipid-lowering candidates, while a Bayer heart failure project gets a high-profile slot despite its discontinuation.
A positive readout for Medtronic's Tyrx envelope could mean an extra $1,000 per cardiac implant in the company's pocket.
Guardant gets a liquid biopsy trial win, but if it wants to drive sales it must get cancer societies on board.
Array Biopharma hopes for a label extension for its Braf/Mek inhibitor, and Proteon tries to make a better fist of its second phase III trial of vonapanitase.
Until now all PD-(L)1 blockers were assumed to have broadly similar activity, with any differences being put down to trial design; the latest renal cancer data could…
Intercept’s Regenerate trial in Nash, one of the hottest clinical readouts of 2019, is technically a success, but toxicity casts a long shadow.
In the Keynote-426 study Merck & Co’s Keytruda looks to have blasted Opdivo out of the water, showing a 47% reduction in risk of death versus Sutent.
In a constrained pricing environment a volume play could help sales of Lilly's Emgality as it takes on Amgen’s Aimovig and Teva’s Ajovy.
But Erleada, Johnson & Johnson’s next-gen prostate cancer therapy, still needs to outperform the incumbent, Zytiga.